BCBSRI Achieved Savings, 5-Star Rating With Help of Embedded ACO Pharmacists

While an unprecedented number of Medicare Advantage Prescription Drug (MA-PD) plans earned a 5-star rating for 2022 largely because of flexibilities granted during the COVID-19 public health emergency, Blue Cross & Blue Shield of Rhode Island (BCBSRI) credits a performance-based pharmacist intervention model with dramatically improving its drug-related scores and contributing to a 5-star summary rating for both of its contracts.

Nearly 70% of Medicare Advantage Prescription Drug (MA-PD) plans earned on overall rating of 4 stars or higher for 2022, when CMS allowed plans to use the better of the two years’ rating (2021 or 2022) for most measures because all contracts qualified for the “extreme and uncontrollable circumstances policy.” Plans will not have that flexibility for the 2023 star ratings due out this fall.